ArticleCancer medicine2025

First-In-Human Dose Finding Study of Venadaparib (IDX-1197), a Potent and Selective PARP Inhibitor, in Patients With Advanced Solid Tumors.

Sung-Bae Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.